102 related articles for article (PubMed ID: 24025562)
1. Current strategies to minimize toxicity of oxaliplatin: selection of pharmacogenomic panel tests.
Di Francia R; Siesto RS; Valente D; Del Buono A; Pugliese S; Cecere S; Cavaliere C; Nasti G; Facchini G; Berretta M
Anticancer Drugs; 2013 Nov; 24(10):1069-78. PubMed ID: 24025562
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenomics panel test for prevention toxicity in patient who receive Fluoropirimidine/Oxaliplatin-based therapy.
Di Francia R; Siesto RS; Valente D; Spart D; Berretta M
Eur Rev Med Pharmacol Sci; 2012 Sep; 16(9):1211-7. PubMed ID: 23047504
[TBL] [Abstract][Full Text] [Related]
3. Pyridoxine to protect from oxaliplatin-induced neurotoxicity without compromising antitumour effect.
Garg MB; Ackland SP
Cancer Chemother Pharmacol; 2011 Apr; 67(4):963-6. PubMed ID: 20976600
[TBL] [Abstract][Full Text] [Related]
4. Oxaliplatin-induced neuropathy in colorectal cancer: many questions with few answers.
Zedan AH; Hansen TF; Fex Svenningsen A; Vilholm OJ
Clin Colorectal Cancer; 2014 Jun; 13(2):73-80. PubMed ID: 24365057
[TBL] [Abstract][Full Text] [Related]
5. Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: results from a prospective multicenter study.
Argyriou AA; Cavaletti G; Antonacopoulou A; Genazzani AA; Briani C; Bruna J; Terrazzino S; Velasco R; Alberti P; Campagnolo M; Lonardi S; Cortinovis D; Cazzaniga M; Santos C; Psaromyalou A; Angelopoulou A; Kalofonos HP
Cancer; 2013 Oct; 119(19):3570-7. PubMed ID: 23821303
[TBL] [Abstract][Full Text] [Related]
6. Rational selection of predictive pharmacogenomics test for the Fluoropyrimidine/Oxaliplatin based therapy.
Di Francia R; De Lucia L; Di Paolo M; Di Martino S; Del Pup L; De Monaco A; Lleshi A; Berretta M
Eur Rev Med Pharmacol Sci; 2015 Nov; 19(22):4443-54. PubMed ID: 26636535
[TBL] [Abstract][Full Text] [Related]
7. Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2.
Sprowl JA; Ciarimboli G; Lancaster CS; Giovinazzo H; Gibson AA; Du G; Janke LJ; Cavaletti G; Shields AF; Sparreboom A
Proc Natl Acad Sci U S A; 2013 Jul; 110(27):11199-204. PubMed ID: 23776246
[TBL] [Abstract][Full Text] [Related]
8. Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients.
Kweekel DM; Gelderblom H; Antonini NF; Van der Straaten T; Nortier JW; Punt CJ; Guchelaar HJ
Eur J Cancer; 2009 Mar; 45(4):572-8. PubMed ID: 19084393
[TBL] [Abstract][Full Text] [Related]
9. Oxaliplatin-induced oxidative stress in nervous system-derived cellular models: could it correlate with in vivo neuropathy?
Di Cesare Mannelli L; Zanardelli M; Failli P; Ghelardini C
Free Radic Biol Med; 2013 Aug; 61():143-50. PubMed ID: 23548635
[TBL] [Abstract][Full Text] [Related]
10. Preventing oxaliplatin-induced neurotoxicity: rationale and design of phase Ib randomized, double-blind, placebo-controlled, cross-over trials for early clinical evaluation of investigational therapeutics.
Han CH; Kilfoyle DH; Hill AG; Jameson MB; McKeage MJ
Expert Opin Drug Metab Toxicol; 2016 Dec; 12(12):1479-1490. PubMed ID: 27539508
[TBL] [Abstract][Full Text] [Related]
11. Literature review and practical aspects on the management of oxaliplatin-associated toxicity.
Hoff PM; Saad ED; Costa F; Coutinho AK; Caponero R; Prolla G; Gansl RC
Clin Colorectal Cancer; 2012 Jun; 11(2):93-100. PubMed ID: 22154408
[TBL] [Abstract][Full Text] [Related]
12. A phase I and pharmacokinetic study of oxaliplatin and bortezomib: activity, but dose-limiting neurotoxicity.
Kobrinsky B; Joseph SO; Muggia F; Liebes L; Beric A; Malankar A; Ivy P; Hochster H
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1073-8. PubMed ID: 24048674
[TBL] [Abstract][Full Text] [Related]
13. The effect of prophylactic calcium and magnesium infusions on the incidence of neurotoxicity and clinical outcome of oxaliplatin-based systemic treatment in advanced colorectal cancer patients.
Knijn N; Tol J; Koopman M; Werter MJ; Imholz AL; Valster FA; Mol L; Vincent AD; Teerenstra S; Punt CJ
Eur J Cancer; 2011 Feb; 47(3):369-74. PubMed ID: 21067912
[TBL] [Abstract][Full Text] [Related]
14. Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer.
Leonard GD; Wright MA; Quinn MG; Fioravanti S; Harold N; Schuler B; Thomas RR; Grem JL
BMC Cancer; 2005 Sep; 5():116. PubMed ID: 16168057
[TBL] [Abstract][Full Text] [Related]
15. Oxaliplatin-related neurotoxicity: how and why?
Pasetto LM; D'Andrea MR; Rossi E; Monfardini S
Crit Rev Oncol Hematol; 2006 Aug; 59(2):159-68. PubMed ID: 16806962
[TBL] [Abstract][Full Text] [Related]
16. Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy.
Kweekel DM; Gelderblom H; Guchelaar HJ
Cancer Treat Rev; 2005 Apr; 31(2):90-105. PubMed ID: 15847979
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and safety profile of oxaliplatin.
Extra JM; Marty M; Brienza S; Misset JL
Semin Oncol; 1998 Apr; 25(2 Suppl 5):13-22. PubMed ID: 9609104
[TBL] [Abstract][Full Text] [Related]
18. Platinum neurotoxicity pharmacogenetics.
McWhinney SR; Goldberg RM; McLeod HL
Mol Cancer Ther; 2009 Jan; 8(1):10-6. PubMed ID: 19139108
[TBL] [Abstract][Full Text] [Related]
19. Characterization of and protection from neurotoxicity induced by oxaliplatin, bortezomib and epothilone-B.
Ceresa C; Avan A; Giovannetti E; Geldof AA; Avan A; Cavaletti G; Peters GJ
Anticancer Res; 2014 Jan; 34(1):517-23. PubMed ID: 24403510
[TBL] [Abstract][Full Text] [Related]
20. The effect of monosialotetrahexosylganglioside (GM1) in prevention of oxaliplatin induced neurotoxicity: a retrospective study.
Chen XF; Wang R; Yin YM; Røe OD; Li J; Zhu LJ; Guo RH; Wu T; Shu YQ
Biomed Pharmacother; 2012 Jun; 66(4):279-84. PubMed ID: 22397758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
